[ad_1]
WASHINGTON — President Biden names Monica M. Bertagnoli, M.D., an oncologist and cancer patient who has run the National Cancer Institute for the past six months, as the next director of the National Institutes of Health. It’s a schedule. He said.
If confirmed by the Senate, Dr. Bertagnoli would become the second woman to serve as a permanent director of the Institute of Medical Research since it was founded in the late 1800s. She is the first female director of the National Cancer Institute, part of the National Institutes of Health.
The White House will announce her selection in the coming days, a senior administration official said. The Wall Street Journal previously reported on her appearance as a Biden nominee.
Dr. Bertagnolli was appointed director of the National Cancer Institute (NCI) in October. Two months later, she received an early-stage breast cancer diagnosis and announced that she would begin her treatment at Boston’s Brigham and Women’s Hospital and Dana’s Farber Cancer Institute. She worked as a surgical oncologist in Boston before she entered the federal government. She said she has a good prognosis.
“I’m currently in a waiting period and there are some things we don’t know,” she said at the time. You’ll get your answer in no time.”
If approved, Dr. Bertagnoli will establish a world-wide body of 27 separate laboratories and centers focused on a wide range of medical issues, including cancer, infectious diseases, heart and lung disease, mental health, and substance abuse. You will lead one of the leading medical research institutions. The annual budget of the National Institutes of Health, a division of the Federal Office of Health and Human Services, exceeds his $47 billion, much of which is scattered around the world to fund basic medical research.
Dr. Bertagnoli will succeed Dr. Lawrence A. Tabak, who has been in the acting role since Dr. Francis S. Collins stepped down at the end of 2021 after more than 12 years as Director.
Only Dr. Bernadine P. Healy, who was appointed by President George H.W. Bush, served as chief of the agency, but longtime federal scientist and NIH administrator Dr. Ruth Kirshstein twice served as acting director. served.
Prior to joining the National Cancer Institute, Dr. Bertagnolli was a professor of surgery at Harvard Medical School, specializing in surgical oncology. Her previous research has focused on the genetic mutations that drive the development of gastrointestinal cancers and the role inflammation plays in cancer growth.
Ellen V. Segal, founder and chairman of Friends of Cancer Research, a research and advocacy group, said she would be very happy if the president chose Dr. Bertagnoli.
“She has all the perspectives you want in an NIH leader,” Sigal said. “She has basic science. She has clinical experience. She has demonstrated leadership ability and she is a patient now.”
[ad_2]
Source link
